TNFRSF18 and neoplasm: Further evidence is provided by a recent study that demonstrated that a bispecific anti–PD-1 mAb-multimeric GITRL conjugate induced PD-1–dependent GITR clustering, enhanced GITR+ PD-1+ T-cell activation, and inhibited tumor growth in a mouse model (53).